Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 7/20 | 0.51 |
| ▸ | AAK1 | Q2M2I8 | 8/20 | 0.50 |
| ▸ | PRCP | P42785 | 3/20 | 0.41 |
| ▸ | RHEB | Q15382 | 1/20 | 0.40 |
| ▸ | PNMT | P11086 | 1/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1519201 | 1.00 | ROCK2 (0.51) | ROCK2AAK1PRCPRHEBPNMT | |
| SCHEMBL1519320 | 0.89 | ROCK2 (0.55) | ROCK2AAK1PRCPROCK1 | |
| SCHEMBL12763520 | 0.89 | ROCK2 (0.55) | ROCK2AAK1PRCPROCK1 | |
| SCHEMBL1519244 | 0.89 | ROCK2 (0.55) | ROCK2AAK1PRCPROCK1 | |
| SCHEMBL1519468 | 0.84 | ROCK2 (0.56) | ROCK2AAK1ROCK1 | |
| SCHEMBL1519150 | 0.84 | ROCK2 (0.54) | ROCK2AAK1ROCK1 | |
| SCHEMBL12836399 | 0.84 | ROCK2 (0.56) | ROCK2AAK1ROCK1 | |
| SCHEMBL1519155 | 0.84 | ROCK2 (0.54) | ROCK2AAK1ROCK1 | |
| SCHEMBL12763518 | 0.84 | ROCK2 (0.54) | ROCK2AAK1ROCK1 | |
| SCHEMBL1519250 | 0.84 | ROCK2 (0.70) | ROCK2AAK1PRCPROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110052562-A1 | BENZIMIDAZOLES AND ANALOGS AS RHO KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-03-03 | — | — | US | disclosed |
| WO-2009079011-A1 | BENZIMIDAZOLES AND ANALOGS AS RHO KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110052562-A1 | BENZIMIDAZOLES AND ANALOGS AS RHO KINASE INHIBITORS | ROCK1, ROCK2, ARHGDIB | ROCK2 2/4885AAK1 532/4885PRCP 3882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.